Integrin Signalling and EBC-46: How Tigilanol Tiglate May Disrupt Cell Adhesion in Tumour Microenvironments

Integrins are a family of transmembrane receptors that mediate cell adhesion to the extracellular matrix and play critical roles in cell migration, proliferation, and survival signalling. In tumour biology, dysregulated integrin signalling contributes to invasion, angiogenesis, and metastatic spread. Emerging research suggests that EBC-46 (tigilanol tiglate), through its established activity on protein kinase C (PKC) isoforms, may indirectly influence integrin-mediated pathways in ways that compromise tumour cell anchorage and viability.

PKC and Integrin Cross-Talk

Protein kinase C enzymes are known regulators of integrin activation and clustering. PKC-mediated phosphorylation events affect the affinity state of integrins, influencing whether cells maintain adhesion to their surrounding matrix. Research published in the Journal of Cell Science has demonstrated that PKC-delta, the isoform most strongly activated by tigilanol tiglate, is directly involved in modulating integrin beta-1 inside-out signalling. When PKC-delta is hyperactivated, the downstream effect can include loss of focal adhesion integrity and detachment-induced apoptosis, a process known as anoikis.

This mechanism is particularly relevant in the context of solid tumours, where cancer cells depend on integrin-ECM interactions for survival signals that suppress apoptotic pathways. Disruption of these interactions — even transiently — can shift the balance toward programmed cell death.

Vascular Endothelial Integrins

Beyond tumour cells themselves, integrins expressed on vascular endothelial cells (notably alpha-v beta-3) are essential for tumour angiogenesis. QBiotics' published research on tigilanol tiglate has documented rapid vascular disruption at injection sites, with haemorrhagic necrosis occurring within hours. While the primary mechanism is attributed to direct PKC activation, the downstream effect on endothelial integrin function likely contributes to the speed and completeness of vascular collapse observed in preclinical models.

From Injectable to Oral: Translating the Science

It is important to note that the integrin-disruption research has been conducted with pharmaceutical-grade injectable tigilanol tiglate at concentrations achievable through direct intratumoral administration. Oral blushwood berry extract supplements contain tigilanol tiglate as one constituent among the broader phytochemical profile of the whole seed. The systemic bioavailability of tigilanol tiglate from oral supplementation has not been characterised in published clinical studies.

Dietary supplements containing blushwood berry extract are marketed under the DSHEA framework as general wellness products, not as treatments targeting specific molecular pathways. Consumers interested in these products should consult a healthcare professional and look for suppliers with transparent third-party testing. Blushwood Health provides Eurofins-verified batch reports for its 10:1 whole-seed extract products.

Related Articles

Explore our coverage of EBC-46 and the PKC-delta destruction pathway and NF-kB suppression by EBC-46 for deeper context on these molecular mechanisms.